Men with type 2 diabetes and low testosterone face a complex treatment landscape where the delivery method may matter as much as the hormone itself. Different testosterone formulations create dramatically different patterns of hormone exposure, potentially influencing metabolic outcomes in ways that standard prescribing practices rarely consider. This comprehensive analysis reveals that transdermal patches and gels produce steady, physiologic testosterone levels that mirror natural circadian rhythms, supporting gradual improvements in insulin sensitivity. The stable hormone exposure enables consistent androgen receptor activation, which appears crucial for sustained metabolic benefits. In contrast, oral testosterone undecanoate creates brief peaks followed by rapid declines, limiting the duration of beneficial metabolic signaling despite achieving adequate average hormone levels. Injectable formulations present a spectrum of effects: short-acting esters generate supraphysiological spikes that can destabilize glucose control through excessive aromatase activity, while long-acting preparations provide prolonged steady exposure similar to transdermal options. The review identifies scrotal application as particularly effective for transdermal delivery, achieving significantly higher systemic levels and dihydrotestosterone conversion compared to other skin sites. For the growing population of diabetic men with hypogonadism—estimated at 25-40% of type 2 diabetics—this pharmacokinetic analysis suggests that delivery method selection could meaningfully impact glycemic control. The findings challenge the common clinical assumption that testosterone formulations are interchangeable, instead suggesting that steady-state kinetics may be essential for optimizing metabolic benefits in this vulnerable population.